Double maintains 2 strategies that include PACB - Pacific Biosciences of California, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CYD | 0.02% | $876.80M | +155.41% | 3.92% |
| ORLY | -0.03% | $77.36B | +30.90% | 0.00% |
| CTRE | -0.04% | $5.84B | +20.16% | 4.10% |
| UL | 0.12% | $150.91B | +12.15% | 3.19% |
| GORV | 0.14% | $27.11M | -91.06% | 0.00% |
| KR | -0.15% | $47.17B | +41.48% | 1.81% |
| WELL | -0.16% | $99.14B | +43.06% | 1.77% |
| GRFS | 0.16% | $2.32B | +38.04% | 0.00% |
| MSI | 0.21% | $71.05B | +10.06% | 1.00% |
| NVS | 0.22% | $233.59B | +15.65% | 3.24% |
| QNTM | 0.27% | $52.38M | +102.20% | 0.00% |
| AZN | 0.32% | $221.62B | -7.18% | 2.19% |
| RLMD | 0.38% | $20.45M | -79.39% | 0.00% |
| AIZ | 0.38% | $10.02B | +19.18% | 1.60% |
| GDDY | 0.42% | $25.42B | +24.81% | 0.00% |
| ATO | 0.42% | $24.41B | +31.87% | 2.24% |
| CHD | 0.57% | $24.05B | -7.40% | 1.18% |
| MDLZ | -0.59% | $89.29B | +4.44% | 2.72% |
| POR | 0.62% | $4.48B | -3.74% | 4.98% |
| DOGZ | 0.63% | $162.32M | -27.35% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -39.21% | $295.67M | 1.43% |
| VIXY | -26.50% | $165.58M | 0.85% |
| TAIL | -25.15% | $99.49M | 0.59% |
| IVOL | -22.75% | $348.25M | 1.02% |
| FTSD | -15.29% | $231.68M | 0.25% |
| SCHO | -14.59% | $11.46B | 0.03% |
| XONE | -14.37% | $585.85M | 0.03% |
| ULST | -14.29% | $658.54M | 0.2% |
| STPZ | -13.98% | $450.05M | 0.2% |
| SPTS | -13.44% | $5.77B | 0.03% |
| FXY | -13.27% | $820.31M | 0.4% |
| IBTH | -13.26% | $1.60B | 0.07% |
| UTWO | -12.40% | $379.27M | 0.15% |
| LDUR | -12.01% | $929.45M | 0.5% |
| AGZ | -11.97% | $613.46M | 0.2% |
| VTIP | -11.83% | $15.34B | 0.03% |
| SHYM | -11.60% | $354.58M | 0.35% |
| VGSH | -11.39% | $22.77B | 0.03% |
| IBTG | -11.25% | $1.92B | 0.07% |
| IEI | -10.78% | $15.41B | 0.15% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 61.11% | $1.02B | 0.75% |
| GNOM | 51.65% | $44.38M | 0.5% |
| IWC | 50.28% | $817.74M | 0.6% |
| XRT | 49.63% | $309.43M | 0.35% |
| GSSC | 48.84% | $560.96M | 0.2% |
| IWM | 48.56% | $63.18B | 0.19% |
| VTWO | 48.43% | $12.58B | 0.07% |
| IWO | 48.39% | $11.53B | 0.24% |
| PBW | 47.55% | $268.39M | 0.65% |
| PRFZ | 47.37% | $2.36B | 0.34% |
| IWN | 47.15% | $10.93B | 0.24% |
| SCHA | 47.09% | $17.26B | 0.04% |
| IJR | 47.04% | $79.19B | 0.06% |
| EES | 46.80% | $584.75M | 0.38% |
| PBE | 46.78% | $223.86M | 0.58% |
| CALF | 46.76% | $4.18B | 0.59% |
| SPSM | 46.76% | $11.31B | 0.03% |
| VIOV | 46.74% | $1.27B | 0.1% |
| IJT | 46.57% | $6.06B | 0.18% |
| DFAS | 46.57% | $10.21B | 0.27% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TIP | 0.03% | $13.96B | 0.18% |
| TFI | 0.03% | $3.21B | 0.23% |
| SCHJ | -0.05% | $527.81M | 0.03% |
| SCHQ | -0.06% | $752.08M | 0.03% |
| ICSH | 0.07% | $6.03B | 0.08% |
| GSST | 0.07% | $919.83M | 0.16% |
| GCOR | -0.08% | $586.96M | 0.08% |
| IGOV | 0.08% | $1.21B | 0.35% |
| FLMI | 0.09% | $723.28M | 0.3% |
| VMBS | -0.10% | $14.44B | 0.03% |
| FISR | -0.13% | $428.82M | 0.5% |
| CGCB | -0.15% | $2.46B | 0.27% |
| KRBN | 0.22% | $162.64M | 0.85% |
| VGLT | 0.25% | $9.76B | 0.04% |
| VTEB | 0.27% | $37.62B | 0.03% |
| BND | 0.35% | $130.90B | 0.03% |
| SPMB | -0.37% | $6.14B | 0.04% |
| HTRB | -0.37% | $2.02B | 0.29% |
| SPTL | 0.46% | $11.23B | 0.03% |
| PSQA | 0.50% | $35.43M | 0.2% |
Yahoo
Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) delivered a presentation at the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 11. The company discussed its financial performance, highlighting both market limitations and growth prospects, […]
Yahoo
Key Insights The projected fair value for Pacific Biosciences of California is US$2.00 based on 2 Stage Free Cash Flow...
Yahoo
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.24, representing a -3.88% change from its previous close.
Yahoo
PacBio’s first quarter of 2025 was shaped by ongoing funding constraints in the academic and research sector, as well as continued uncertainty in global capital equipment spending. Management pointed to declining instrument sales—particularly Revio system placements—as a direct consequence of weaker academic budgets, especially in the United States. CEO Christian Henry highlighted that, “The Academic and Research Institute segment represented the lowest percentage of instrument shipments since t
Yahoo
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Yahoo
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -29.25% | $24.29B | +35.36% | 1.09% |
| ED | -16.65% | $36.31B | +13.27% | 3.35% |
| DUK | -16.23% | $92.39B | +19.10% | 3.55% |
| CME | -16.02% | $99.25B | +39.75% | 3.87% |
| MCK | -14.63% | $90.90B | +24.44% | 0.39% |
| IFRX | -13.30% | $53.71M | -53.76% | 0.00% |
| EXC | -12.96% | $43.82B | +25.72% | 3.63% |
| SO | -12.46% | $101.44B | +19.02% | 3.16% |
| PGR | -12.18% | $154.94B | +25.19% | 1.87% |
| MO | -11.84% | $97.93B | +26.25% | 6.95% |
| HLN | -10.38% | $46.54B | +24.25% | 1.73% |
| CL | -10.21% | $74.59B | -4.24% | 2.20% |
| AMT | -10.18% | $105.08B | +16.75% | 2.96% |
| PPL | -10.09% | $25.13B | +23.96% | 3.15% |
| PULM | -9.62% | $24.14M | +230.50% | 0.00% |
| T | -9.09% | $207.81B | +53.45% | 3.83% |
| TEF | -8.75% | $30.02B | +27.27% | 6.13% |
| K | -8.52% | $27.71B | +40.85% | 2.85% |
| ALL | -8.17% | $53.00B | +24.95% | 1.94% |
| VZ | -7.41% | $184.17B | +6.28% | 6.15% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TXG | 58.01% | $1.51B | -36.09% | 0.00% |
| BEAM | 53.26% | $1.76B | -22.33% | 0.00% |
| CRSP | 48.89% | $4.19B | -8.67% | 0.00% |
| ILMN | 48.35% | $15.54B | -6.98% | 0.00% |
| SITE | 47.77% | $5.66B | +8.32% | 0.00% |
| AZTA | 47.74% | $1.45B | -38.37% | 0.00% |
| CRBU | 47.72% | $116.26M | -21.88% | 0.00% |
| LAB | 46.83% | $489.97M | -27.12% | 0.00% |
| RXRX | 46.66% | $2.09B | -28.35% | 0.00% |
| DNA | 45.58% | $630.84M | -18.04% | 0.00% |
| ABG | 45.33% | $4.89B | +9.51% | 0.00% |
| BKE | 45.24% | $2.41B | +36.60% | 2.99% |
| ALLO | 44.39% | $258.10M | -45.37% | 0.00% |
| TECH | 44.24% | $8.16B | -26.90% | 0.62% |
| BRKR | 44.08% | $6.35B | -32.02% | 0.48% |
| KN | 43.80% | $1.54B | +3.74% | 0.00% |
| CERS | 43.69% | $282.92M | -12.94% | 0.00% |
| PCOR | 43.59% | $10.39B | +2.50% | 0.00% |
| ABCL | 43.45% | $1.04B | +25.99% | 0.00% |
| NTLA | 43.39% | $1.02B | -55.40% | 0.00% |
Current Value
$1.311 Year Return
Current Value
$1.311 Year Return
